ASCO 2026: Why Experts Say Galleri Multi-Cancer Test Isn’t Ready Yet
At ASCO 2026, Grail’s Galleri multi-cancer blood test showed promise but missed its main goal in the large NHS trial. Experts say it’s not ready for broad population screening yet.
/ 6 items
#GRAL↓
TD Cowen Turns Bullish on Grail: Upgrade to Buy After 60% Plunge Creates Bargain Entry
TD Cowen upgrades Grail to Buy from Hold with $65 target after 60% selloff. Analyst sees attractive entry in multi-cancer detection despite NHS study miss.
GRAIL Tumbles as NHS-Galleri Trial Fails Primary Endpoint
GRAIL shares plunged 38% after hours despite promising NHS-Galleri trial results. The blood test missed its main goal but cut late-stage cancers and boosted early detection 4x.
Hims Adds Cancer Detection Test to Labs Product
Hims & Hers partners with Grail to offer discounted Galleri cancer detection tests through its Labs subscription service, expanding beyond weight-loss treatments.
Guggenheim Upgrades Grail to Buy with $100 Target on Galleri’s Market Leadership
Guggenheim upgrades Grail to Buy with a $100 price target, citing Galleri’s strong market position in multi-cancer early detection (MCED) despite ongoing regulatory and reimbursement challenges.
Galleri Blood Test Detects 7X More Cancers | GRAIL PATHFINDER 2 Results
GRAIL's Galleri blood test increases cancer detection by over 7-fold when added to routine screenings, catching more than 50 cancer types early when most treatable. PATHFINDER 2 study shows breakthrough results.